Since Bifidobacterium bifidum, one of the strains of medical preparations used for human intestinal disorders, is sensitive to rifampicin (RFP) and fluoroquinolones, its therapeutic effect cannot be guaranteed when it is administered concomitantly with these antibiotics. To develop new strains of B. bifidum that are resistant to these drugs, B. bifidum RFR61, which is highly resistant to RFP, was selected by the N-methyl-N'-nitrosoguanidine (MNNG) mutation method. Then, B. bifidum OFR9 was selected in vitro from B. bifidum RFR61 by serial passage to increasing concentrations of ofloxacin (OFLX) on a solid medium. The minimal inhibition concentrations (MIC) of RFP and fluoroquinolones for B. bifidum OFR9 were >256 mg/ml and 16-256 &mgr;g/ml, respectively. We investigated the effects of B. bifidum OFR9 on the fecal bacterial flora of mice administered with both antibiotics and B. bifidum OFR9. The results showed that the concurrent use of B. bifidum OFR9 and antibiotics prevented the decrease of bifidobacteria, and quickly restored the flora to normal as compared with the use of antibiotic or parent strain therapy alone. The survival of Shigella organisms in mouse feces rapidly decreased, and were removed within two days as a result of the oral administration of B. bifidum OFR9.